A dysregulated inflammatory response is observed in various diseases, such as rheumatoid arthritis, diabetes, cancer, and Alzheimer's disease as well as pulmonary, cardiovascular, and autoimmune diseases. Inflammation involves a complex network of many mediators, a variety of cells, and execution of multiple pathways.
Traditionally, therapeutic regimens for inflammation include the use of steroidal and non-steroidal anti-inflammatory agents. However, these drugs may provoke severe adverse effects, including osteoporosis, gastrointestinal abnormalities, cardiovascular events, and renal disorders. Moreover, drug resistance may occur in a subpopulation of patients. There is an urgent need to explore new anti-inflammatory agents with selective effects and lower toxicity. Although various in vivo and in vitro models are available for anti-inflammatory drug development, wise selection of appropriate animal models is a key step in the early phase of drug development.
Creative Bioarray offers a large number of validated acute, chronic and immune-mediated pharmacological models and a series of preclinical services, enabling customers to screen potential anti-inflammatory agents as well as identify novel therapeutic targets. Screening of compounds can be performed in existing well-characterized animal models or in newly developed animal models customized for specific test items.
Inflammatory Bowel Disease (IBD) Models
- Dextran sodium sulfate (DSS)-induced colitis
- 2,4,6-Trinitrobenzene sulfonic acid (TNBS)-induced colitis
- Indomethacin-induced intestinal inflammation
Arthritis Models
- Collagen-induced arthritis (CIA)
- Collagen antibody-induced arthritis
- Adjuvant-induced arthritis (AIA)
- Pristane-induced arthritis (PIA)
- Ovalbumin-induced arthritis (OIA)
Multiple Sclerosis Models
- Myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalitis (EAE)
- Myelin basic protein (MBP)-induced EAE
- Proteolipid protein (PLP)-induced EAE
Systemic Lupus Erythematosus (SLE) Models
- MRL/Lpr
- NZB/W F1
- Pristane-induced lupus
Sepsis Models
- Lipopolysaccharide (LPS)-induced sepsis
- Cecal ligation and puncture (CLP)-induced sepsis
Highlights:
- Comprehensive selection of acute and chronic inflammation models
- Multiple mechanisms of inflammatory and autoimmune diseases
- Innate and regulatory cell-mediated models
- Robust determination of efficacy and response to treatment
- Expert model selection and research design consultation
We work closely with scientists from academic institutions, pharmaceutical industries or biotechnology companies. Our expert scientists are able to combine different disease models to provide unparalleled ability to distinguish the mode of action of novel compounds. Combining models, such as IBD, fibrosis or asthma, along with biomarker readouts may quickly and cost-effectively reveal a putative mode of action.
Our customer service representatives are available 24 hours a day, 7 days a week.
Inquiry
For research use only. Not for any other purpose.
Related Services:
